Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Items 201–300 of 1,000
Recent advances on the encoding and selection methods of DNA-encoded chemical library
Shi, B., Zhou, Y., Huang, Y., Zhang, J.-F., & Li, X. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.025 · Cited by 74
Nuisance Compounds, PAINS Filters, and Dark Chemical Matter in the GSK HTS Collection
Chakravorty, S. J., Chan, J., Greenwood, M. N., Popa-Burke, I. G., Remlinger, K. S., Pickett, S. D., Green, D. V. S., Fillmore, M. C., Dean, T. W., Luengo, J. I., et al. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218768497 · Cited by 67
“High-throughput screening (HTS) is a critical tool in the identification of lead molecules for novel therapeutic targets in drug discovery.(1,2) Over the past 20 years GlaxoSmithKline (GSK) has continuously invested in the development and curation of its HTS collection.”
Self-citationTang, S., & Kim, P. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916916116 · Cited by 70
Bohni, N., Cordero-Maldonado, M. L., Maes, J., Siverio-Mota, D., Marcourt, L., Munck, S., Kamuhabwa, A. R., Moshi, M. J., Esguerra, C. V., de Witte, P. A. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064006 · Cited by 66
“In contrast, the isolation and characterization of bioactive secondary metabolites present in complex NP extracts involves the application of several complementary methodologies that require considerably more time and effort [4,5].”
Improving Screening Efficiency through Iterative Screening Using Docking and Conformal Prediction
Svensson, F., Norinder, U., & Bender, A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00532 · Cited by 65
Aguisanda, F., Thorne, N., & Zheng, W. (2017) · Current Chemical Genomics · doi:10.2174/2213988501711010001 · Cited by 72
“High throughput drug screening (HTS) of chemical libraries is a potential method for rapid identification of active compounds (“hits”) that ameliorate disease phenotypes in patient-derived cells [104].”
BackgroundThe upside of being a digital pharma player
Schuhmacher, A., Gatto, A., Hinder, M., Kuss, M., & Gassmann, O. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.002 · Cited by 62
Broad Coverage of Commercially Available Lead-like Screening Space with Fewer than 350,000 Compounds
Baell, J. B. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300461a · Cited by 69
Nanomaterials for Biosensors and Implantable Biodevices
Luz, R. A. S., Iost, R. M., & Crespilho, F. N. (2012) · Springer eBooks · doi:10.1007/978-3-642-29250-7_2 · Cited by 79
Hepatitis E Virus Drug Development
Kinast, V., Burkard, T. L., Tödt, D., & Steinmann, E. (2019) · Viruses · doi:10.3390/v11060485 · Cited by 65
“NITD008 has been reported to act as an antiviral on numerous viruses, amongst others HCV [32], West Nile Virus [33] or Zika [34].”
BackgroundInfluentialScreening-Based Translation of Public Research Encounters Painful Problems
Baell, J. B. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00032 · Cited by 65
Discovery of De Novo Macrocyclic Peptides by Messenger RNA Display
Peacock, H., & Suga, H. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.02.004 · Cited by 64
“Traditionally, screening approaches rely on the high-throughput analysis of large collections of synthetic molecules or natural products [15], and, more recently, of small chemical fragments [16] or ‘ virtual ’ collections of ligands [17].”
FINDSITEcomb: A Threading/Structure-Based, Proteomic-Scale Virtual Ligand Screening Approach
Zhou, H., & Skolnick, J. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300510n · Cited by 63
Kuenemann, M. A., Spérandio, O., Labbé, C. M., Lagorce, D., Miteva, M. A., & Villoutreix, B. O. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.02.006 · Cited by 64
Advanced tools in marine natural drug discovery
Zhang, G., Li, J., Zhu, T., Gu, Q., & Li, D. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.021 · Cited by 74
Deep clustering of small molecules at large-scale via variational autoencoder embedding and K-means
Hadipour, H., Liu, C., Davis, R. L., Cardona, S. T., & Hu, P. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04667-1 · Cited by 75
“In the practice of drug discovery, high-throughput screening (HTS) is the primary approach for identifying drug candidates from chemical libraries [1].”
BackgroundEstablished and Emerging Trends in Computational Drug Discovery in the Structural Genomics Era
Taboureau, O., Baell, J. B., Fernández‐Recio, J., & Villoutreix, B. O. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.007 · Cited by 69
Application of a Dual-Arm Robot in Complex Sample Preparation and Measurement Processes
Fleischer, H., Drews, R. R., Janson, J., Patlolla, B. R. C., Chu, X., Klös, M., & Thurow, K. (2016) · SLAS TECHNOLOGY · doi:10.1177/2211068216637352 · Cited by 63
Therapeutic potential of pteridine derivatives: A comprehensive review
Carmona‐Martínez, V., Ruiz‐Alcaraz, A. J., Vera, M., Guirado, A., Martinez‐Esparza, M., & García–Peñarrubia, P. (2018) · Medicinal Research Reviews · doi:10.1002/med.21529 · Cited by 66
“The availability of HTS techniques has facilitated the screening of huge and varied drug libraries against cell panels to identify drug candidates for clinical development.(179) In this sense, as shown in Table 6, several pteridine derivatives are under investigation in clinical trials as therapeutic agent candidates…”
BackgroundMorato, N. M., Le, M. T., Holden, D. T., & Cooks, R. G. (2021) · SLAS TECHNOLOGY · doi:10.1177/24726303211047839 · Cited by 62
“78 When data acquisition is complete, the DESI plate can be (1) discarded, (2) stored for later reanalysis, or (3) immediately reanalyzed (e.”
BackgroundMethodResultInfluentialRecent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics
Prajapati, R. N., Bhushan, B., Singh, K., Chopra, H., Kumar, S., Agrawal, M., Pathak, D., Chanchal, D. K., & Kant, L. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010275850240102105033 · Cited by 76
Active machine learning-driven experimentation to determine compound effects on protein patterns
Naik, A. W., Kangas, J. D., Sullivan, D. P., & Murphy, R. F. (2016) · eLife · doi:10.7554/elife.10047 · Cited by 69
“…candidate screens identify compounds that perturb a particular target in a desired way, but their possible off-target or side-effects are not measured during the screening process and are often only discovered late in drug development ( Lounkine et al., 2012 ; Macarron et al., 2011 ; Trist, 2011 ).”
BackgroundResultTailored therapeutics based on 1,2,3-1 H -triazoles: a mini review
Prasher, P., & Sharma, M. (2019) · MedChemComm · doi:10.1039/c9md00218a · Cited by 64
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Yang, H., Chen, X., Li, K., Cheaito, H. A., Yang, Q., Wu, G., Liu, J., & Dou, Q. P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.013 · Cited by 65
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18091271 · Cited by 61
“Hit identification from millions of potential compounds demands efficient screening strategies [15].”
Melillo, B. N., Zoller, J., Hua, B. K., Verho, O., Borghs, J. C., Nelson, S. D., Maetani, M., Wawer, M. J., Clemons, P. A., & Schreiber, S. L. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b07319 · Cited by 70
“20 Both enantiomers of azetidine-2-carboxylic acid (1) were N-protected and”
Machine learning for target discovery in drug development
Rodrigues, T., & Bernardes, G. J. L. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.10.003 · Cited by 61
“With the advent of high-throughput experimentation, a wealth of chemical and biological data has been generated [16,28,29].”
BackgroundDrug Repurposing for Triple-Negative Breast Cancer
Ávalos-Moreno, M., López-Tejada, A., Blaya-Cánovas, J. L., Cara, F. E., González-González, A., Lorente, J. A., Sánchez‐Rovira, P., & Granados-Principal, S. M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040200 · Cited by 64
“including high-throughput screening [25] and methods based on experimental findings and previous literature, e.”
MethodHigh throughput screening of enzyme activity with mass spectrometry imaging
de Rond, T., Danielewicz, M. A., & Northen, T. R. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.07.008 · Cited by 64
Yeast Synthetic Biology Platform Generates Novel Chemical Structures as Scaffolds for Drug Discovery
Klein, J., Heal, J. R., Hamilton, W. D. O., Boussemghoune, T., Tange, T. Ø., Delegrange, F., Jaeschke, G., Hatsch, A., & Heim, J. (2014) · ACS Synthetic Biology · doi:10.1021/sb400177x · Cited by 60
Labanieh, L., Nguyen, T., Zhao, W., & Kang, D. (2015) · Micromachines · doi:10.3390/mi6101431 · Cited by 63
“However, they require expensive and bulky robotic machinery and suffer from sample evaporation and comparably large reaction volumes, which can waste precious biological samples or reagents [1,2].”
BackgroundDavid, L., Arús-Pous, J., Karlsson, J., Engkvist, O., Bjerrum, E. J., Kogej, T., Kriegl, J. M., Beck, B., & Chen, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01303 · Cited by 57
“…have seen an acceleration of compound data generation in pharmaceutical industry driven by the technical advancement of HTS (Mayr and Bojanic, 2009; Macarron et al., 2011), parallel chemical synthesis (Borman, 1999), as well as the by the introduction of automation in sequencing and imaging.”
BackgroundInfluentialNatural Products as Modulators of Sirtuins
Karaman, B., Sippl, W., & Ntie‐Kang, F. (2020) · Molecules · doi:10.3390/molecules25143287 · Cited by 66
“HTS and did not need prior information about the target and the ligands [6].”
BackgroundInfluentialTrends in Hit-to-Lead Optimization Following DNA-Encoded Library Screens
Reiher, C. A., Schuman, D. P., Simmons, N., & Wolkenberg, S. E. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00615 · Cited by 60
Patterned superhydrophobic surfaces to process and characterize biomaterials and 3D cell culture
Neto, A. I., Levkin, P. A., & Mano, J. F. (2018) · Materials Horizons · doi:10.1039/c7mh00877e · Cited by 60
A high-throughput platform for efficient exploration of functional polypeptide chemical space
Wu, G., Zhou, H., Zhang, J., Tian, Z., Liu, X., Wang, S., Coley, C. W., & Lu, H. (2023) · Nature Synthesis · doi:10.1038/s44160-023-00294-7 · Cited by 60
Peptide Shuttles for Blood–Brain Barrier Drug Delivery
Sánchez‐Navarro, M., & Giralt, E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091874 · Cited by 58
“High-throughput screening techniques have sped up the development of therapeutics during the last few decades [89].”
BackgroundBiodiversity of small molecules – a new perspective in screening set selection
Petrone, P., Wassermann, A. M., Lounkine, E., Kutchukian, P. S., Simms, B., Jenkins, J. L., Selzer, P. M., & Glick, M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.02.005 · Cited by 58
Ekins, S., Freundlich, J. S., Hobrath, J. V., Lucile White, E., & Reynolds, R. C. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1172-7 · Cited by 56
Orthotopic models of pediatric brain tumors in zebrafish
Eden, C., Ju, B. H., Murugesan, M., Phoenix, T. N., Nimmervoll, B. V., Tong, Y., Ellison, D. W., Finkelstein, D., Wright, K. D., Boulos, N., et al. (2014) · Oncogene · doi:10.1038/onc.2014.107 · Cited by 58
Osborne, J., Panova, S., Rapti, M., Urushima, T., & Jhoti, H. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190694 · Cited by 58
Explainable artificial intelligence for precision medicine in acute myeloid leukemia
Gimeno, M., José‐Eneriz, E. S., Villar, S., Agirre, X., Prósper, F., Rubio, A., & Carazo, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.977358 · Cited by 60
“(2) Generate individual Drug-Biomarker Associations using IHW, (3) Multiple-pair analysis that generates a patient stratification guideline using a novel MILP model (IHW: Independent Hypothesis Weighting, MILP: Mixed-integer Linear Programming).”
Ni-catalyzed ligand-controlled divergent and selective synthesis
Ke, Y., Li, W., Liu, W., & Kong, W. (2023) · Science China Chemistry · doi:10.1007/s11426-023-1533-y · Cited by 57
Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening
Theodoraki, M. A., Rezende, C. O., Chantarasriwong, O., Corben, A. D., Theodorakis, E. A., & Alpaugh, M. L. (2015) · Oncotarget · doi:10.18632/oncotarget.4013 · Cited by 57
Ekins, S., Reynolds, R. C., Franzblau, S. G., Wan, B., Freundlich, J. S., & Bunin, B. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063240 · Cited by 55
“3 mM [10] and 25 mM [11], as seen elsewhere in high-throughput screening (HTS) and infectious disease drug discovery [15–17].”
Quantification of Frequent-Hitter Behavior Based on Historical High-Throughput Screening Data
Nissink, J. W. M., & Blackburn, S. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.72 · Cited by 57
Li, G., Zhang, Z., Quan, Q., Jiang, R., Szeto, S. S. W., Yuan, S., Wong, W., Lam, H. C., Lee, S. M., & Chu, I. K. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00152 · Cited by 59
Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts
Mer, A. S., Ba-Alawi, W., Smirnov, P., Wang, Y. X., Brew, B., Ortmann, J., Tsao, M.-S., Cescon, D. W., Goldenberg, A., & Haibe-Kains, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0349 · Cited by 59
Computational Approaches for De Novo Drug Design: Past, Present, and Future
Liu, X., IJzerman, A. P., & van Westen, G. J. P. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0826-5_6 · Cited by 64
Revolutionizing peptide‐based drug discovery: Advances in the post‐AlphaFold era
Chang, L., Mondal, A., Singh, B., Martínez‐Noa, Y., & Perez, A. (2024) · WIREs Computational Molecular Science · doi:10.1002/wcms.1693 · Cited by 56
Fernald, K., Förster, P. C., Claassen, E., & van de Burgwal, L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104160 · Cited by 65
Li, G., Diogo, D., Wu, D., Spoonamore, J., Dancik, V., Franke, L., Kurreeman, F., Rossin, E. J., Duclos, G., Hartland, C., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003487 · Cited by 55
“First, the chemical library tested in our study is small relative to libraries in academic centers and industry (which often contain hundreds of thousands to millions of compounds) [57,58].”
BackgroundScaffold Diversity of Fungal Metabolites
González-Medina, M., Owen, J. R., El‐Elimat, T., Pearce, C. J., Oberlies, N. H., Figueroa, M., & Medina‐Franco, J. L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00180 · Cited by 56
“Many research groups are investing in enhancing their collections by adding compounds with different chemotypes rather than simply increasing the size of their compound libraries (Macarron et al., 2011).”
BackgroundFollmann, M., Briem, H., Steinmeyer, A., Hillisch, A., Schmitt, M. H., Haning, H., & Meier, H. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.12.003 · Cited by 53
Computational Chemistry on a Budget: Supporting Drug Discovery with Limited Resources
Willems, H. M. G., Cesco, S. D., & Svensson, F. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02126 · Cited by 65
“19 However, due to the high costs, this method has been out of reach for many academic labs and smaller biotechs.”
BackgroundDrone approach parameters leading to lower stress sheep flocking and movement: sky shepherding
Yaxley, K. J., Joiner, K. F., & Abbass, H. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-87453-y · Cited by 55
Discovery of KV1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges
Gubič, Š., Hendrickx, L. A., Toplak, Ž., Sterle, M., Peigneur, S., Tomašič, T., Pardo, L. A., Tytgat, J., Zega, A., & Mašič, L. P. (2021) · Medicinal Research Reviews · doi:10.1002/med.21800 · Cited by 61
“As the probability of acquiring a potential hit compound from HTS is low, the financial investment is high, and the strategy is time‐consuming, sometimes knowledge‐based approaches have a better likelihood of success.(167,168) Hit compounds from the exploitation of biological information have been obtained from resear…”
BackgroundKomatsu, T., & Urano, Y. (2015) · Analytical Sciences · doi:10.2116/analsci.31.257 · Cited by 57
Container-based bioinformatics with Pachyderm
Novella, J. A., Khoonsari, P. E., Herman, S., Whitenack, D., Capuccini, M., Burman, J., Kultima, K., & Spjuth, O. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty699 · Cited by 55
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
Zhou, X., Qu, M., Tebon, P. J., Jiang, X., Wang, C., Xue, Y., Zhu, J., Zhang, S., Öklü, R., Sengupta, S., et al. (2020) · Advanced Science · doi:10.1002/advs.202001447 · Cited by 60
Quantum chemical calculations for reaction prediction in the development of synthetic methodologies
Hayashi, H., Maeda, S., & Mita, T. (2023) · Chemical Science · doi:10.1039/d3sc03319h · Cited by 56
Harris, S. B., Biswas, A., Yun, S. J., Roccapriore, K. M., Rouleau, C. M., Puretzky, A. A., Vasudevan, R. K., Geohegan, D. B., & Xiao, K. (2024) · Small Methods · doi:10.1002/smtd.202301763 · Cited by 54
The Current State of Drug Discovery and a Potential Role for NMR Metabolomics
Powers, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401803b · Cited by 62
Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors
Anantpadma, M., Kouznetsova, J., Wang, H., Huang, R., Kolokoltsov, A. A., Guha, R., Lindstrom, A., Shtanko, O., Simeonov, A. M., Maloney, D. J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00543-16 · Cited by 54
Applied metabolomics in drug discovery
Cuperlovic-Culf, M., & Culf, A. S. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1195365 · Cited by 54
“High throughput screening had several successes [63,64] particularly for finding highly specific inhibitors of popular protein targets.”
BackgroundNMR-Fragment Based Virtual Screening: A Brief Overview
Singh, M., Tam, B., & Akabayov, B. (2018) · Molecules · doi:10.3390/molecules23020233 · Cited by 57
“In particular, high-throughput screening (HTS) became a dominant approach for the discovery of hit molecules [19].”
BackgroundAutonomous optimization of an organic solar cell in a 4-dimensional parameter space
Osterrieder, T., Schmitt, F., Lüer, L., Wagner, J., Heumueller, T., Hauch, J., & Brabec, C. J. (2023) · Energy & Environmental Science · doi:10.1039/d3ee02027d · Cited by 55
Streamlining bioactive molecular discovery through integration and automation
Chow, S. Y., Liver, S., & Nelson, A. S. (2018) · Nature Reviews Chemistry · doi:10.1038/s41570-018-0025-7 · Cited by 56
PubChem BioAssay: A Decade’s Development toward Open High-Throughput Screening Data Sharing
Wang, Y., Cheng, T., & Bryant, S. H. (2017) · SLAS DISCOVERY · doi:10.1177/2472555216685069 · Cited by 52
“High-throughput screening (HTS) is a key technology for drug discovery that allows researchers to test hundreds of thousands of samples.(1) Screening of diverse libraries of small molecules has proven to be an essential method for identifying chemical starting points for early-stage drug discovery.”
BackgroundDong, Z. Q., & Fang, Q. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.115812 · Cited by 52
Pollen molecular biology: Applications in the forensic palynology and future prospects: A review
Alotaibi, S. S., Sayed, S. M. H., Alosaimi, M. E., Alharthi, R., Banjar, A., Abdulqader, N., & Alhamed, R. A. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.02.019 · Cited by 52
Kernel Methods for Predicting Yields of Chemical Reactions
Haywood, A. L., Redshaw, J., Hanson‐Heine, M. W. D., Taylor, A. R., Brown, A., Mason, A. M., Gärtner, T., & Hirst, J. D. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00699 · Cited by 58
Application of computational methods for anticancer drug discovery, design, and optimization
Prada‐Gracia, D., Huerta‐Yépez, S., & Moreno‐Vargas, L. M. (2016) · Boletín Médico Del Hospital Infantil de México (English Edition) · doi:10.1016/j.bmhime.2017.11.040 · Cited by 58
Zimmermann, M. O., Lange, A., Wilcken, R., Cieslik, M. B., Exner, T. E., Joerger, A. C., Koch, P., & Boeckler, F. M. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.20 · Cited by 58
Precision Hydrogels for the Study of Cancer Cell Mechanobiology
Sievers, J., Mahajan, V., Welzel, P. B., Werner, C., & Taubenberger, A. V. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202514 · Cited by 53
Inhibition of Microglia Activation as a Phenotypic Assay in Early Drug Discovery
Figuera-Losada, M., Rojas, C., & Slusher, B. S. (2014) · SLAS Discovery · doi:10.1177/1087057113499406 · Cited by 49
“Considering that the number of pharmaceutical programs that used PAs as primary screening assays was much smaller than those employing target-based assays, the implications are that the former strategy is significantly more successful at producing new drugs.(3,5,6) PA-based approaches have been particularly effective…”
BackgroundZhang, Z., Chen, Y., Urs, S., Chen, L., Simeone, D. M., & Yoon, E. (2018) · Small · doi:10.1002/smll.201703617 · Cited by 55
Hit Dexter: A Machine‐Learning Model for the Prediction of Frequent Hitters
Stork, C., Wagner, J., Friedrich, N., Kops, C. D. B., Šícho, M., & Kirchmair, J. (2017) · ChemMedChem · doi:10.1002/cmdc.201700673 · Cited by 51
Chemistry‐driven Hit‐to‐lead Optimization Guided by Structure‐based Approaches
Hoffer, L., Müller, C., Roche, P., & Morelli, X. (2018) · Molecular Informatics · doi:10.1002/minf.201800059 · Cited by 50
Augmenting DMTA using predictive AI modelling at AstraZeneca
Ghiandoni, G. M., Evertsson, E., Riley, D. J., Tyrchan, C., & Rathi, P. C. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103945 · Cited by 50
Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108107 · Cited by 61
Gul, S., & Hadian, K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.954544 · Cited by 54
“Many of the chemical starting points of recent clinically approved drugs have originated from high-throughput screening (HTS) campaigns that made use of microtiter plate-based assays against libraries of small molecules [19,20].”
BackgroundWangchareansak, T., Thitithanyanont, A., Chuakheaw, D., Gleeson, M. P., Lieberzeit, P. A., & Sangma, C. (2014) · MedChemComm · doi:10.1039/c3md00272a · Cited by 49
Quality control of cell-based high-throughput drug screening
Zhang, Z., Guan, N., Li, T., Mais, D. E., & Wang, M. (2012) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2012.03.006 · Cited by 62
Abbasov, M. E., Hudson, B. M., Tantillo, D. J., & Romo, D. (2016) · Chemical Science · doi:10.1039/c6sc04273b · Cited by 49
Pitchai, A., Rajaretinam, R. K., & Freeman, J. L. (2019) · Medicines · doi:10.3390/medicines6020061 · Cited by 54
“In complex NP extracts, the isolation and structural characterization of bioactive small molecules involves several new methodologies that need considerable time and effort [10,11].”
BackgroundDroplet splitting in microfluidics: A review
Agnihotri, S. N., Raveshi, M. R., Nosrati, R., Bhardwaj, R., & Neild, A. (2025) · Physics of Fluids · doi:10.1063/5.0267868 · Cited by 51
Small Molecule Screening in Human Induced Pluripotent Stem Cell-derived Terminal Cell Types
Engle, S. J., & Vincent, F. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.529156 · Cited by 56
Natural Product Libraries: Assembly, Maintenance, and Screening.
Butler, M. S., Fontaine, F. R., & Cooper, M. A. (2013) · Planta Medica · doi:10.1055/s-0033-1360109 · Cited by 55
“During this time, HTS has had an impact on drug discovery leading to the identification of numerous new drugs leads and at least 12 drugs on the market [22].”
Strategies in the Search for New Lead Compounds or Original Working Hypotheses
Wermuth, C. G., Villoutreix, B. O., Grisoni, S., Olivier, A., & Rocher, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00004-3 · Cited by 55
ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma
Huynh, T., Norris, M. D., Haber, M., & Henderson, M. J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00178 · Cited by 50
“High-throughput screens commonly involve rapidly testing tens of thousands of potential drug candidates in targetbased or cell-based assays with the aim of identifying potentially active compounds from large compound collections (Macarron et al., 2011).”
BackgroundRenner, H., Schöler, H. R., & Bruder, J. M. (2021) · Movement Disorders · doi:10.1002/mds.28775 · Cited by 49
“Modern drug development often relies on highthroughput screening (HTS), that is, the robotically assisted testing of large numbers of compounds (up to hundreds of thousands or more) in vitro, to identify potential new drug candidates.(10,11) To achieve this, all HTS campaigns share common requirements: (1) large numbe…”
BackgroundRxRx1: A Dataset for Evaluating Experimental Batch Correction Methods
Sypetkowski, M., Rezanejad, M., Saberian, S., Kraus, O. Z., Urbanik, J., Taylor, J., Mabey, B., Victors, M. L., Yosinski, J., Sereshkeh, A. R., et al. (2023) · IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops (CVPRW) · doi:10.1109/cvprw59228.2023.00451 · Cited by 75
“High-throughput screening is commonly used in many biological fields, including genetics [18, 53] and drug discovery [5, 7, 36, 49].”
BackgroundQian, R., Xue, J., Xu, Y. C., & Huang, J. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01024 · Cited by 52
Bhakat, S., Karubiu, W., Jayaprakash, V., & Soliman, M. E. S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.010 · Cited by 48
“The use of high throughput screening, natural plant products, synthetic products and computer-aided drug design to speed up identification of novel drug compounds has beenwell documented after the successful application of these methods in the development of maraviroc [20], artemisinin [21], HIV-protease inhibitors an…”
BackgroundPlasmodium Gametocyte Inhibition Identified from a Natural-Product-Based Fragment Library
Vu, H., Roullier, C., Campitelli, M. R., Trenholme, K. R., Gardiner, D. L., Andrews, K. T., Skinner‐Adams, T. S., Crowther, G. J., Voorhis, W. C. V., & Quinn, R. J. (2013) · ACS Chemical Biology · doi:10.1021/cb400582b · Cited by 47
Understanding Cytotoxicity and Cytostaticity in a High-Throughput Screening Collection
Mervin, L., Cao, Q., Barrett, I. P., Firth, M. A., Murray, D., McWilliams, L. J., Haddrick, M., Wigglesworth, M. J., Engkvist, O., & Bender, A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00538 · Cited by 52
Photochemical “In‐Air” Combinatorial Discovery of Antimicrobial Co‐polymers
Richards, S., Jones, A. R., Tomás, R. M. F., & Gibson, M. I. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201802594 · Cited by 47
Targeting protein-protein interaction interfaces in COVID-19 drug discovery
Chang, C., Lin, S., Satange, R., Lin, S., Sun, S.-C., Wu, H., Kehn‐Hall, K., & Hou, M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.003 · Cited by 48
“High-throughput screening (HTS) experiments and virtual screening are widely used approaches in traditional drug discovery [63,64].”
Albani, F. G., Alghamdi, S. S., Almutairi, M. M., & Alqahtani, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s509769 · Cited by 52
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.